Clin2
NCT04528355Possibly a fitRecruiting

Study of hospital data after stem cell transplant for non-cancer illness

Primary Immunodeficiency (PID)Congenital Bone Marrow Failure SyndromesInherited Metabolic Disorders (IMD)Hereditary AnemiasInflammatory Conditions

Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Digestive system, Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy, Skin clinical trials.

This study collects medical information from people with certain non-cancer conditions who receive a stem cell transplant. It may help doctors better understand transplant outcomes and care, since the study focuses on data collection rather than adding new treatment.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
50 people
Ages
2 months to 60 years
Study type
Observational

Who can take part

  • You (or your parent/legal guardian) must give written consent to join.
  • Your age must be 2 months to 60 years at the time of consent.
  • You must have a non-cancer condition that can be treated with stem cell transplant.
  • Examples include immune problems, inherited blood disorders, certain metabolism/storage diseases, or serious inflammatory bowel/immune conditions.
  • You must receive a stem cell transplant using reduced-intensity conditioning in the way described at UPMC Children’s Hospital of Pittsburgh.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT01962415Recruiting· Phase 2
Reduced-intensity stem cell transplant for non-cancer disorders

This trial tests whether a gentler (reduced-intensity) conditioning treatment before a stem cell transplant works for non-cancer diseases. It uses specific donor stem cell matches and checks heart, lung, liver, and kidney function to help lower transplant stress while still aiming for benefit.

Pittsburgh, Pennsylvania
NCT07284641Recruiting· Phase 2
Stem cell transplant for immune disorders

This trial tests a stem cell transplant to treat common variable immunodeficiency (CVID) and other immune problems. It aims to replace a faulty immune system with a healthy one from a donor.

Pittsburgh, Pennsylvania
NCT01890486Recruiting
Collecting information from people having a stem cell transplant

This study aims to collect, store, and share data from patients who are receiving standard intensive treatment and a stem cell transplant from either their own cells or a donor. It may help improve how future patients are treated by building a reliable record of outcomes and care patterns.

Winston-Salem, North Carolina
NCT04232085Recruiting· Phase 2
Stem cell transplant to rebuild immunity in genetic immune disorders

This Phase 2 trial tests a stem cell (bone marrow) transplant approach to restore bone marrow function and immune function in people with certain inherited immune problems. If you have one of these conditions and a suitable donor, the study may offer a path to rebuild blood and immune systems.

Baltimore, Maryland
NCT02579967Recruiting· Phase 2
Stem cell transplant for primary immune system disorders

This study tests whether an allogeneic stem cell (bone marrow) transplant can correct an inherited immune problem in people with severe primary immunodeficiencies. It may help reduce life-threatening infections and improve quality of life, depending on your overall health and donor match.

Bethesda, Maryland
NCT03314974Recruiting· Phase 2
Stem cell transplant study for blood cancers

This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.

Minneapolis, Minnesota

Hear when a new Congenital Bone Marrow Failure Syndromes trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.